Skip to main content

Month: February 2024

UPDATE — IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000. Holders of the Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter, or 8% per year. Each share of Series A Preferred Stock will be convertible into twenty (20) shares of our common stock (“Common Stock) at the option of the holder, subject to certain conditions in accordance with the requirements of the Toronto Stock Exchange....

Continue reading

ILUS Signs Letter of Intent to Acquire a British Manufacturer of Autonomous Vehicles While Completing its Next Phase of Restructuring for Anticipated Growth

NEW YORK, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – ILUS International Inc. (OTC: ILUS) is a Mergers and Acquisitions company focused on acquiring and growing companies in the public safety, industrial, defense and renewable sectors. On February 16, 2024, the Company signed a letter of intent with a British company which has manufacturing and assembly facilities in the United Arab Emirates from which it manufactures and supplies autonomous vehicles as well as defense and public safety solutions. The definitive agreement is expected to be signed in the first quarter of 2024 and is currently intended to be structured as an equity deal of $3,000,000 with a mutually agreed leak out agreement which is expected to come into effect sometime after the intended in-progress business combination agreement with a NASDAQ...

Continue reading

SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024

BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research....

Continue reading

UPDATE – Vianet Deploys DZS Award-Winning Velocity V6 Fiber Access System to Deliver its Customers Multi-Gigabit Bandwidth Capabilities

High capacity, high density DZS fiber access system provides Vianet subscribers some of the fastest bandwidth speeds available in northern Ontario DALLAS, Feb. 20, 2024 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of access, optical and AI-driven cloud software solutions, today announced that Vianet, an Ontario, Canada-based regional communications service provider, is deploying the award-winning DZS Velocity V6 fiber access system to deliver its residential and business customers some of the fastest broadband speeds in northern Ontario. Leveraging the DZS Velocity V6 fiber access system provides Vianet with a clear path to multi-gigabit services leveraging Passive Optical Networking (PON) technology, including symmetric 10 gigabit per second (10 Gbps) capable XGS-PON. “We are in a fiercely competitive market, so we want...

Continue reading

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. “We are thrilled to be presenting at this prestigious international neurology conference, including new baseline biomarker data on ATH434 from our ongoing...

Continue reading

Canon Solutions America Recognized by William Paterson University for Contributions to Russ Berrie Institute for Professional Sales

Long-term support for students and the school’s National Sales Challenge has led to an influx of young sales talent to the companyMichael MellusiMichael Mellusi, vice president, Sales, Workplace Technologies and Services, Canon Solutions America, Inc. was recognized by William Paterson University for his contributions to the sales profession.MELVILLE, N.Y., Feb. 20, 2024 (GLOBE NEWSWIRE) — Simulating an environment that can emulate the landscape for a sales representative can be a challenge, but William Paterson University’s Russ Berrie Institute for Professional Sales continues to prepare the next generation of professionals with the on-going support of Canon Solutions America, Inc., a wholly owned subsidiary of Canon U.S.A., Inc. William Paterson University’s Cotsakos College of Business, located in Wayne, New Jersey,...

Continue reading

Sun Country Airlines Extends its Fall Booking Schedule

Now serving over 100 destinations from Minneapolis-St. Paul MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Sun Country Airlines (NASDAQ: SNCY) is extending its selling schedule through December 10, 2024, allowing customers to book fall travel including Thanksgiving and Minnesota’s popular Oct. 17-20 school break long weekend. In addition, Sun Country has bolstered its schedules to leading travel destinations starting later this summer. Joining Sun Country’s growing list of new destinations from Minneapolis-St. Paul International Airport (MSP) is Monterey Regional Airport (MRY) in California and Manchester-Boston Regional Airport (MHT) in New Hampshire. “Sun Country proudly offers nonstop service from MSP to more than 100 destinations in 2024 giving our customers, and community an unparalleled breadth of destinations for a leisure...

Continue reading

The Marquie Group Ventures into the Growing Nootropics Beverage Sector

ST. PETERSBURG, Fla., Feb. 20, 2024 (GLOBE NEWSWIRE) — The Marquie Group, Inc. (OTCMKTS:TMGI), also known as TMGI or the Company, is excited to announce that it is entering the burgeoning nootropic beverage market with the development of its Insanitea and Sanitea brands. Nootropics, gaining significant traction for their holistic health benefits, are functional ingredients aimed at enhancing cognitive performance. They are becoming a crucial component of comprehensive health and wellness routines. Marc Angell, CEO of The Marquie Group, highlighted the cognitive benefits of natural nootropics found in tea, such as L-theanine from green tea, known for its ability to improve attention, performance, sleep, reaction times, and relaxation. “With consumers seeking healthier alternatives to traditional sports drinks, our nootropic-based...

Continue reading

LiveCare Inc. (OTCMKTS: LVCE) Announces Stellar Revenue Growth, Strategic Patient Expansion in Telehealth for Diabetes Care, and Aspirations for NASDAQ Listing

Venice, FL, USA, Feb. 20, 2024 (GLOBE NEWSWIRE) — LiveCare Inc. (OTCMKTS: LVCE), a leading telehealth company specializing in health coaching and comprehensive services for individuals with diabetes, is thrilled to announce significant achievements and future goals. The company has reported a current revenue of $3.3 million, with an ambitious projection of $12 million for the fiscal year 2024, showcasing an unparalleled growth trajectory in the telehealth sector. LiveCare’s innovative approach to diabetes management has been a key driver of its success, enrolling 50 new patients daily into its programs at a rate of $150 per month per patient. This rapid expansion is a clear indication of the high demand for specialized healthcare services that cater directly to the needs of those living with diabetes. Through personalized...

Continue reading

Global Patent Analytics Market to Surpass USD 2099.3 million by 2030 Driven by Increasing Research and Development

SkyQuest projects that the global patent analytics market will attain a value of USD 2099.3 million by 2030, with a CAGR of 12.7% during the forecast period (2024-2031). The increasing research and development (R&D) activity in healthcare, manufacturing, information technology and telecommunications, among others has accelerated the demand for analytical tools. End users in these sectors invest heavily by filing for IP rights prior to launching their new products. These trends are creating more opportunities for key players in the global patent analytics market. For example, according to the Samsung Electronics 2021 Business Report, the company will invest around 100,000 US dollars. invested $17.38 billion in R&D by 2021 and had 47,900 Korean patents and 10,000 U.S. patents. 84,202 patents added to the company’s 216,404 patents...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.